<DOC>
	<DOCNO>NCT02096913</DOCNO>
	<brief_summary>The Ibuprofen - Spinal Cord Injury ( SCI ) - Safety trial investigate tolerability feasibility `` small molecule '' ( Ibuprofen ) mediate Rho-inhibition putative neuroprotective , plasticity-enhancing neurorestaurative intervention . The primary safety analysis base incidence severe gastrointestinal bleeding . In addition , feasibility recruitment procedure , oral administration compound within multidisciplinary set acute intensive medical care explore . Furthermore , pharmacokinetics Ibuprofen condition acute motor complete SCI investigate . Secondary endpoint permit preliminary statement effect neuropathic pain , spasticity , neurological function .</brief_summary>
	<brief_title>Safety Study Ibuprofen Treat Acute Traumatic Spinal Cord Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Acute SCI cervical spine due trauma Time frame 421 day posttrauma Motor complete injury AIS A B Neurological level lesion C4T4 No participation different clinical trial accord German Pharmaceuticals Act ( AMG ) 1 month participation current trial The patient inform his/her write consent obtain Age : 18 65 year For woman reproductive age : Negative pregnancy test highly effective contraception ( define Pearl Index &lt; 1 ) sexual abstinence participation trial Multifocal lesion spinal cord Penetrating spinal cord injury Accompanying traumatic brain injury ( TBI ) visible structural lesion include intracranial hemorrhage diagnostic imagesSigni Significant accompany injury peripheral nervous system , particularly plexus lesion Acute chronic systemic disease accompany neurological deficit cause permanent neurological deficit may overlay hind registration sensomotor function ( e.g . multiple sclerosis , GuillainBarré syndrome , HIV infection , Lues etc . ) Malignant neoplasm , except complete remission . Mental disease dementia , investigator 's opinion , limit patient 's cooperation respect intake study medication and/or significantly hind registration followup parameter Hemophilia History myocardial infarction stroke Current persistent misuse illegal drug alcohol Hypothermia 35 C° Pregnancy lactation All contraindication study medication , include ingredient pharmaceutical form accord Summary Product Characteristics ( SPC ) Known hypersensitivity active substance contain concomitant medication Pantoprazole one component drug . Intake Ibuprofen intake active substance group Nonsteroidal Antiinflammatory Drugs ( NSAIDs ; e.g. , Diclofenac , Indometacin ) intake NSAIDs maximum recommend daily dos one week prior enrolment trial Simultaneous intake salicylate , particularly acetylsalicylic acid Simultaneous intake oral anticoagulant Simultaneous intake systemic glucocorticoid Unwilling consent storage transfer pseudonymized medical data purpose clinical trial Admitted institution court official order ( pursuant AMG §40 ( 1 ) 4 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rho-Inhibition</keyword>
	<keyword>Plasticity</keyword>
	<keyword>Neurological Function</keyword>
	<keyword>RhoA</keyword>
	<keyword>Ibuprofen</keyword>
	<keyword>NSAIDs</keyword>
</DOC>